At the Forefront

Social Workers’ Role in Psilocybin Treatment for Depression and Substance Misuse

Datos Bibliográficos

ID10554102
AutoresClaire Parker (0000-0002-7364-7046, School of Social Work, University of Texas at Arlington Claire Parker is a social work student, , 501 West Mitchell Street, Arlington, TX 76010, USA, autor de correspondencia), Bethany M Wood (0000-0003-1367-0508, The University of Texas at Arlington)
Año2024
Volumen69
Número3
Páginas297-302
Fecha de publicación2024-05-02
Peer ReviewedSí
Open AccessSí
TipoARTICLE
RevistaSocial Work (JOURNAL)
Identificadores de la revistaISSN: 0037-8046 • E-ISSN: 1545-6846
EditorialOxford University Press (OUP) (PUBLISHER)
DOI10.1093/sw/swae019
PMID38697188
OpenAlexW4396599639
IdiomaEN
Citas recibidas1
Referencias citadas31

This article underscores the critical role of social workers in harnessing the potential therapeutic benefits of psilocybin for treating major depressive disorder (MDD) and substance use disorder (SUD). Contemporary treatments for MDD often have side effects, and the success rate for SUD treatments remains low. The pervasiveness of MDD, combined with the challenges in treating SUD, highlights a need for innovative treatments. This article provides an overview of the resurgence of literature over the past two decades that illuminates the therapeutic promise of psilocybin for mental health treatment; clinical trials elucidate the efficacy of psilocybin-assisted therapy in mitigating MDD and demonstrate great promise in reducing SUD symptoms. The long-lasting posttreatment effect emphasizes its potential as a novel treatment modality. Furthermore, psilocybin's recognition as a "breakthrough therapy" by the U.S. Food and Drug Administration (FDA) and the accelerating pace of psychedelic reform bills indicate growing acceptance and interest in its therapeutic capacities. Psilocybin-assisted therapy emerges as a potent treatment option, showcasing remarkable effectiveness even after a single dose. Recommendations and pathways for social workers to be involved in psilocybin-assisted therapy investigation, advocacy, and implementation are provided

Cognition · Hallucinogen · Major depressive disorder · Psilocybin · Psychiatry · Psychotherapist · Substance abuse · Chemical synthesis and alkaloids · Medicine · Neurotransmitter Receptor Influence on Behavior · Psychedelics and Drug Studies · Psychology